Eulalia Gine-Cipres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eulalia Gine-Cipres has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Pozo-Rosich
Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain
7 shared publications - Edoardo Caronna
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
6 shared publications - Marta Torres-Ferrus
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
6 shared publications - Victor José Gallardo
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
6 shared publications - Alicia Alpuente
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
5 shared publications Alicia Alpuente Ruiz
Headache Unit, Neurology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain
2 shared publications
Latest Publications
- 15 September 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2090-2102
Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross‐sectional study
Background and Objectives: Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. Methods: A cross‐sectional study was conducted including females aged 18–60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen‐only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross‐checked with medical records and phone interviews. Age‐ and size‐matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. Results: A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p ‐values > 0.05). Among females in the RS and regular menstrual cycles ( n = 78), menstrually‐related migraine was highly prevalent (67/78; 86%). In the RS group comparisons ( n = 109), no differences according to HT use in migraine characteristics or menstruation‐related symptoms were observed (all adjusted p ‐values > 0.05). Similarly, among females in the menopause transition ( n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p ‐values > 0.05). Conclusions: In this real‐world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually‐related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.
- 15 September 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2090-2102
Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross‐sectional study
Background and Objectives: Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. Methods: A cross‐sectional study was conducted including females aged 18–60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen‐only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross‐checked with medical records and phone interviews. Age‐ and size‐matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. Results: A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p ‐values > 0.05). Among females in the RS and regular menstrual cycles ( n = 78), menstrually‐related migraine was highly prevalent (67/78; 86%). In the RS group comparisons ( n = 109), no differences according to HT use in migraine characteristics or menstruation‐related symptoms were observed (all adjusted p ‐values > 0.05). Similarly, among females in the menopause transition ( n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p ‐values > 0.05). Conclusions: In this real‐world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually‐related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.
- Open Access
- 25 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70654
Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
- 25 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70654
Open AccessErenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
- Open Access
- 16 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Brain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine
Structural neuroimaging findings in migraine remain heterogeneous, and the impact of preventive treatments such as erenumab and onabotulinumtoxinA (OnabotA
- 16 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessBrain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine
Structural neuroimaging findings in migraine remain heterogeneous, and the impact of preventive treatments such as erenumab and onabotulinumtoxinA (OnabotA
- Open Access
- 14 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Multimodal serum and MRI signatures of neuroaxonal injury in high-frequency migraine
It remains unclear whether high-frequency migraine is associated with objective markers of possible neuroaxonal injury and potential expression of neurodeg
- 14 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessMultimodal serum and MRI signatures of neuroaxonal injury in high-frequency migraine
It remains unclear whether high-frequency migraine is associated with objective markers of possible neuroaxonal injury and potential expression of neurodeg
- Open Access
- 10 March 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (3) , 45618
Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration
Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.
- 10 March 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (3) , 45618
Open AccessOptimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration
Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.
- 10 January 2025
- Published by Elsevier in Pain Management Nursing
- Vol. 26 (3) , 306-311
Quality of Headache Management in Inpatients
- 10 January 2025
- Published by Elsevier in Pain Management Nursing
- Vol. 26 (3) , 306-311
Quality of Headache Management in Inpatients
- 26 April 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (7) , 1937-1944
Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome
Background and purpose: The response pattern to monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAbs) shown in migraine prevention clinical trials is not always reproducible at an individual level. This study was undertaken to describe patterns of start and consistency of the response to anti‐CGRP MAbs during the first 6 months of treatment and the association with baseline clinical characteristics.Methods: This is a prospective clinical cohort observational study. We included migraine patients treated with erenumab or galcanezumab evaluated at baseline and after 3 and 6 months (M3, M6) of treatment. The response was categorized according to reduction in monthly headache days (MHD): Sustained‐response (SustainedR, ≥50% at M3 and M6), Short‐Response (ShortR, M3 ≥50% and M6 <50%), Late‐Response (LateR, M3 <50% and M6 ≥50%), Limited‐Response (LimitedR, 25%–50% at M3 and M6), and No‐Response (NoR, <25% at M3 and M6). Response patterns were compared at baseline and with outcome variables at M3 and M6.Results: We included 357 patients with a headache frequency of 21.0 (interquartile range = 16.0–28.0) MHD, and 84.0% (300/357) were chronic migraine. The distribution according to response pattern was 37.0% (110/297) SustainedR, 16.8% (50/297) LateR, 10.4% (31/297) ShortR, 22.6% (67/297) LimitedR, and 13.1% NoR (39/297). The SustainedR and LateR groups showed statistically significant anxiety and depression score reduction at M3 and M6 compared to the other groups.Conclusions: Initial response to anti‐CGRP MAbs is not consistent in all patients. Persistence of anxiety and depression might be associated with lower response rates at M6.
- 26 April 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (7) , 1937-1944
Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome
Background and purpose: The response pattern to monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAbs) shown in migraine prevention clinical trials is not always reproducible at an individual level. This study was undertaken to describe patterns of start and consistency of the response to anti‐CGRP MAbs during the first 6 months of treatment and the association with baseline clinical characteristics.Methods: This is a prospective clinical cohort observational study. We included migraine patients treated with erenumab or galcanezumab evaluated at baseline and after 3 and 6 months (M3, M6) of treatment. The response was categorized according to reduction in monthly headache days (MHD): Sustained‐response (SustainedR, ≥50% at M3 and M6), Short‐Response (ShortR, M3 ≥50% and M6 <50%), Late‐Response (LateR, M3 <50% and M6 ≥50%), Limited‐Response (LimitedR, 25%–50% at M3 and M6), and No‐Response (NoR, <25% at M3 and M6). Response patterns were compared at baseline and with outcome variables at M3 and M6.Results: We included 357 patients with a headache frequency of 21.0 (interquartile range = 16.0–28.0) MHD, and 84.0% (300/357) were chronic migraine. The distribution according to response pattern was 37.0% (110/297) SustainedR, 16.8% (50/297) LateR, 10.4% (31/297) ShortR, 22.6% (67/297) LimitedR, and 13.1% NoR (39/297). The SustainedR and LateR groups showed statistically significant anxiety and depression score reduction at M3 and M6 compared to the other groups.Conclusions: Initial response to anti‐CGRP MAbs is not consistent in all patients. Persistence of anxiety and depression might be associated with lower response rates at M6.